OpenAI-backed Nabla Bio's JAM-2 AI model designs antibodies ready for human trials, potentially revolutionizing drug ...
VYD2311 met all primary and secondary endpoints comparing VYD2311 to an mRNA-based COVID-19 vaccine, demonstrating VYD2311 safety and ...
Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a biopharmaceutical company dedicated to the discovery, development, manufacturing, ...
Innovent Biologics, Inc. announced updated Phase 1 clinical data for IBI3003, a novel trispecific antibody targeting GPRC5D, BCMA, and CD3, in patients with relapsed or refractory multiple myeloma ...
Lung cancer remains the deadliest malignancy worldwide, and non-small cell lung cancer (NSCLC) accounts for roughly 85 ...
Blood plasma has long been the workhorse of clinical diagnostics, a fluid so rich in molecular information that a single draw ...
This article explores how advances in antibody engineering are moving immunotherapy beyond traditional monoclonal antibodies to bispecific and trispecific formats and logic-gated designs.
BOSTON--The Institute for Protein Innovation (IPI), a nonprofit research organization advancing protein science to accelerate biomedical research and improve human health, today announced the ...
Nurix entered into the collaboration with Seagen Inc., now part of Pfizer, in September 2023. Under the terms of the agreement, Nurix received an upfront payment of $60 million and became eligible to ...
Peanut allergy is one of the most serious food allergies and can lead to sudden, life-threatening reactions. Researchers from ...
FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases HONG KONG and SHANGHAI and ...
ASC50 is an in-house discovered and developed oral small molecule inhibitor targeting IL-17A, an important biologically and commercially validated target for multiple autoimmune and inflammatory ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results